IFP Advisors
ARQT icon

IFP Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

IFP Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.84K Hold
183
– – ﹤0.01% 3836
2026
Q2 		$4.8K Sell
183
-111
-38% -$2.59K ﹤0.01% 3822
2026
Q1 		$6.93K Sell
294
-7
-2% -$179 ﹤0.01% 3349
2025
Q4 		$8.74K Buy
301
+110
+58% +$2.82K ﹤0.01% 3132
2025
Q3 		$3.6K Buy
191
+4
+2% +$63 ﹤0.01% 3435
2025
Q2 		$2.62K Buy
187
+174
+1,338% +$2.44K ﹤0.01% 3767
2025
Q1 		$203 Hold
13
– – ﹤0.01% 3664
2024
Q4 		$181 Buy
+13
New +$142 ﹤0.01% 3791

Other funds holding ARQT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

IFP Advisors's ARQT Position: Q3 2026 in Review

IFP Advisors held its Arcutis Biotherapeutics (ARQT) position steady in Q3 2026 at 183 shares worth $4.84K. The position accounts for ﹤0.01% of the portfolio, ranked #3836.

IFP Advisors first reported a position in ARQT in Q4 2024 and has held it in 8 quarters since. The position peaked at $8.74K in Q4 2025. 212 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

  • IFP Advisors held 183 shares of Arcutis Biotherapeutics worth $4.84K as of Q3 2026.
  • IFP Advisors left its Arcutis Biotherapeutics share count unchanged in Q3 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #3836 holding.
  • IFP Advisors first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 8 quarters since.
  • IFP Advisors's Arcutis Biotherapeutics position peaked at $8.74K in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.